June 25, 2021
1 min watch
Save
VIDEO: Presbyopia drug progresses through clinical trials
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
DENVER – Orasis Pharmaceutical President and COO Paul Smith told Healio here at Optometry’s Meeting that the company is proceeding from positive phase 2 study results to enrollment for a phase 3 protocol.
He said Orasis obtained funding that allowed them to initiate the NEAR-1 and NEAR-2 studies.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Smith is employed by Orasis.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.